BLU.TO - BELLUS Health Inc.
| Previous Close | 14.28 |
| Open | 14.70 |
| Bid | 14.06 x 0 |
| Ask | 14.17 x 0 |
| Day's Range | 14.05 - 15.18 |
| 52 Week Range | 3.97 - 16.68 |
| Volume | 72,592 |
| Avg. Volume | 121,090 |
| Market Cap | 852.909M |
| Beta (5Y Monthly) | 0.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.73 |
| Earnings Date | May 05, 2020 - May 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.82 |
- Simply Wall St.
We Think BELLUS Health (TSE:BLU) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. Indeed, BELLUS Health...
- Business Wire
BELLUS Health Announces Completion of Dosing in Phase 2 RELIEF Trial with BLU-5937 for the Treatment of Refractory Chronic Cough
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (the "Company" or "BELLUS Health") , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it has completed patient dosing in its Phase 2 RELIEF clinical trial of BLU-5937 for the treatment of refractory chronic cough, with 52 patients completing treatment. The Company decided to close the trial early due to the impact of the COVID-19 pandemic on the RELIEF clinical trial activities. The Company continues to expect topline data from the trial mid-year 2020.
- Business Wire
BELLUS Health Announces Closing of Transaction to Acquire Remaining Intellectual Property Rights to BLU-5937 from adMare BioInnovations
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (the "Company" or "BELLUS Health") is pleased to announce that it has closed the transaction announced on March 23, 2020 (the "Transaction") in accordance with the asset purchase and sale agreement entered into with adMare BioInnovations’ NEOMED Institute ("adMare").
- Baystreet
BELLUS, Mint at 52-Week Highs
BELLUS Health Inc. (T.BLU) hit a new 52-week high of $14.81 Tuesday. No news stories today. Royal ...
- Business Wire
BELLUS Health Announces Transaction to Acquire Remaining Intellectual Property Rights to BLU-5937 from adMare BioInnovations
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (the "Company" or "BELLUS Health"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it has entered into an asset purchase and sale agreement to acquire all of the remaining BLU-5937 and related P2X3 antagonists intellectual property assets (the "BLU-5937 Assets") from adMare BioInnovations’ NEOMED Institute ("adMare") (the "Transaction").
- Baystreet
Stocks in play: BELLUS Health Inc.
Has completed patient enrollment for the RELIEF trial, its dose-escalation, placebo-controlled Phase ...
- Business Wire
BELLUS Health Announces Completion of Enrollment in Phase 2 RELIEF Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (the "Company" or "BELLUS Health"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it has completed patient enrollment for the RELIEF trial, its dose-escalation, placebo-controlled Phase 2 trial of BLU-5937 in patients with refractory chronic cough.
- Simply Wall St.
Have Insiders Been Buying BELLUS Health Inc. (TSE:BLU) Shares This Year?
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
- Simply Wall St.
Should You Worry About BELLUS Health Inc.'s (TSE:BLU) CEO Salary Level?
In 2010 Roberto Bellini was appointed CEO of BELLUS Health Inc. (TSE:BLU). This report will, first, examine the CEO...
- The Motley Fool
Canada Revenue Agency: 1 Major TFSA Mistake Could Cost You Thousands
The Alacer Gold and Bellus Health stocks are showing strong earnings potential.
- Simply Wall St.
The BELLUS Health (TSE:BLU) Share Price Gained 1027% And Shareholders Are Jubilant
Investing can be hard but the potential fo an individual stock to pay off big time inspires us. Mistakes are...
- The Motley Fool
This Little-Known Stock Increased Over 100% in 2019!
With a novel drug to treat two severe cough conditions under development, the potential gains from the Bellus Health stock could be enormously huge.
- The Motley Fool
This Biotech Stock Is Set to Climb 500%
Bellus Health Inc. (TSX:BLU) could be the rising star of the biotech sector and the general market come 2020. Its lead drug candidate is a potential blockbuster.
- The Motley Fool
Trudeau’s Drug Price Overhaul Threatens This Company
BELLUS Health Inc. (TSX:BLU) is the latest revelation on the TSX. The healthcare stock is soaring this year. We hope the growth would continue and not be slowed down by the political uncertainties in Canada.
- Simply Wall St.
Does BELLUS Health Inc. (TSE:BLU) Have A Particularly Volatile Share Price?
If you're interested in BELLUS Health Inc. (TSE:BLU), then you might want to consider its beta (a measure of share...
